Literature DB >> 25091747

Pulmonary arterial hypertension treatment guidelines: new answers and even more questions.

Anna R Hemnes1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25091747      PMCID： PMC4137589          DOI： 10.1378/chest.14-1440

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  14 in total

1.  Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.

Authors:  Hossein-Ardeschir Ghofrani; Andrea M D'Armini; Friedrich Grimminger; Marius M Hoeper; Pavel Jansa; Nick H Kim; Eckhard Mayer; Gerald Simonneau; Martin R Wilkins; Arno Fritsch; Dieter Neuser; Gerrit Weimann; Chen Wang
Journal:  N Engl J Med       Date:  2013-07-25       Impact factor: 91.245

2.  Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.

Authors:  Olivier Sitbon; Marc Humbert; Xavier Jaïs; Vincent Ioos; Abdul M Hamid; Steeve Provencher; Gilles Garcia; Florence Parent; Philippe Hervé; Gérald Simonneau
Journal:  Circulation       Date:  2005-06-06       Impact factor: 29.690

3.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

Authors:  R M Califf; K F Adams; W J McKenna; M Gheorghiade; B F Uretsky; S E McNulty; H Darius; K Schulman; F Zannad; E Handberg-Thurmond; F E Harrell; W Wheeler; J Soler-Soler; K Swedberg
Journal:  Am Heart J       Date:  1997-07       Impact factor: 4.749

4.  BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Kevin K Brown; Ganesh Raghu; Roland M du Bois; David A Lynch; Fernando Martinez; Dominique Valeyre; Isabelle Leconte; Adele Morganti; Sébastien Roux; Juergen Behr
Journal:  Am J Respir Crit Care Med       Date:  2011-04-07       Impact factor: 21.405

5.  ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association.

Authors:  Vallerie V McLaughlin; Stephen L Archer; David B Badesch; Robyn J Barst; Harrison W Farber; Jonathan R Lindner; Michael A Mathier; Michael D McGoon; Myung H Park; Robert S Rosenson; Lewis J Rubin; Victor F Tapson; John Varga
Journal:  J Am Coll Cardiol       Date:  2009-04-28       Impact factor: 24.094

6.  Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.

Authors:  N Galiè; Lj Rubin; Mm Hoeper; P Jansa; H Al-Hiti; Gmb Meyer; E Chiossi; A Kusic-Pajic; G Simonneau
Journal:  Lancet       Date:  2008-06-21       Impact factor: 79.321

7.  Causes and circumstances of death in pulmonary arterial hypertension.

Authors:  Adriano R Tonelli; Vineesha Arelli; Omar A Minai; Jennie Newman; Nancy Bair; Gustavo A Heresi; Raed A Dweik
Journal:  Am J Respir Crit Care Med       Date:  2013-08-01       Impact factor: 21.405

8.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.

Authors:  R J Barst; L J Rubin; W A Long; M D McGoon; S Rich; D B Badesch; B M Groves; V F Tapson; R C Bourge; B H Brundage; S K Koerner; D Langleben; C A Keller; S Murali; B F Uretsky; L M Clayton; M M Jöbsis; S D Blackburn; D Shortino; J W Crow
Journal:  N Engl J Med       Date:  1996-02-01       Impact factor: 91.245

Review 9.  Updated evidence-based treatment algorithm in pulmonary arterial hypertension.

Authors:  Robyn J Barst; J Simon R Gibbs; Hossein A Ghofrani; Marius M Hoeper; Vallerie V McLaughlin; Lewis J Rubin; Olivier Sitbon; Victor F Tapson; Nazzareno Galiè
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

10.  Pulmonary hypertension surveillance: United States, 2001 to 2010.

Authors:  Mary G George; Linda J Schieb; Carma Ayala; Anjali Talwalkar; Shaleah Levant
Journal:  Chest       Date:  2014-08       Impact factor: 9.410
View more
  2 in total

1.  The echocardiographic course of pretransplant pulmonary hypertension following kidney transplantation and associated outcomes.

Authors:  Adaani E Frost; Linda W Moore; Miguel Valdivia E Alvarado; Chizoba Obi; Edward A Graviss; Duc T Nguyen; Ahmed Osama Gaber; Wadi N Suki
Journal:  Pulm Circ       Date:  2022-02-08       Impact factor: 2.886

Review 2.  Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review.

Authors:  Adam M Henrie; James J Nawarskas; Joe R Anderson
Journal:  Core Evid       Date:  2015-11-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.